vs
Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and NUSCALE POWER Corp (SMR). Click either name above to swap in a different company.
Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $8.2M, roughly 1.5× NUSCALE POWER Corp). Avidity Biosciences, Inc. runs the higher net margin — -1398.3% vs -3316.2%, a 1917.8% gap on every dollar of revenue. On growth, NUSCALE POWER Corp posted the faster year-over-year revenue change (1635.2% vs 434.0%). Avidity Biosciences, Inc. produced more free cash flow last quarter ($-156.9M vs $-199.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 22.4%).
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
NuScale Power Corporation is a publicly traded American company that designs and markets small modular reactors (SMRs). It is headquartered in Tigard, Oregon. The company's VOYGR power plant, which uses 50 MWe modules and scales to 12 modules, was the first SMR to be certified by the US Nuclear Regulatory Commission (NRC) (2022). The newer 77 MWe module designs, known as the VOYGR-4 and VOYGR-6, were submitted for NRC review on January 1, 2023, and approved May 29, 2025. NuScale is now seekin...
RNA vs SMR — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $8.2M |
| Net Profit | $-174.4M | $-273.3M |
| Gross Margin | — | 32.9% |
| Operating Margin | -1513.5% | -6532.9% |
| Net Margin | -1398.3% | -3316.2% |
| Revenue YoY | 434.0% | 1635.2% |
| Net Profit YoY | -117.0% | -1465.5% |
| EPS (diluted) | $-1.27 | $-1.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $12.5M | $8.2M | ||
| Q2 25 | $3.8M | $8.1M | ||
| Q1 25 | $1.6M | $13.4M | ||
| Q4 24 | $3.0M | $34.2M | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.5M | — | ||
| Q4 23 | $2.2M | $4.6M |
| Q3 25 | $-174.4M | $-273.3M | ||
| Q2 25 | $-157.3M | $-17.6M | ||
| Q1 25 | $-115.8M | $-14.0M | ||
| Q4 24 | $-102.3M | $-75.0M | ||
| Q3 24 | $-80.4M | — | ||
| Q2 24 | $-70.8M | — | ||
| Q1 24 | $-68.9M | — | ||
| Q4 23 | $-60.4M | $-18.8M |
| Q3 25 | — | 32.9% | ||
| Q2 25 | — | 22.1% | ||
| Q1 25 | — | 52.4% | ||
| Q4 24 | — | 91.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 15.8% |
| Q3 25 | -1513.5% | -6532.9% | ||
| Q2 25 | -4448.7% | -534.9% | ||
| Q1 25 | -8360.9% | -264.1% | ||
| Q4 24 | -4069.6% | -34.6% | ||
| Q3 24 | -4200.9% | — | ||
| Q2 24 | -4040.4% | — | ||
| Q1 24 | -2178.6% | — | ||
| Q4 23 | -3043.5% | -1558.2% |
| Q3 25 | -1398.3% | -3316.2% | ||
| Q2 25 | -4089.3% | -219.0% | ||
| Q1 25 | -7360.0% | -104.7% | ||
| Q4 24 | -3439.5% | -219.1% | ||
| Q3 24 | -3441.7% | — | ||
| Q2 24 | -3461.8% | — | ||
| Q1 24 | -1943.4% | — | ||
| Q4 23 | -2756.2% | -411.3% |
| Q3 25 | $-1.27 | $-1.85 | ||
| Q2 25 | $-1.21 | $-0.13 | ||
| Q1 25 | $-0.90 | $-0.11 | ||
| Q4 24 | $-0.80 | $-0.77 | ||
| Q3 24 | $-0.65 | — | ||
| Q2 24 | $-0.65 | — | ||
| Q1 24 | $-0.79 | — | ||
| Q4 23 | $-0.80 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $350.2M | $691.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $828.7M |
| Total Assets | $2.1B | $883.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $350.2M | $691.8M | ||
| Q2 25 | $243.9M | $420.7M | ||
| Q1 25 | $254.2M | $521.4M | ||
| Q4 24 | $219.9M | $441.6M | ||
| Q3 24 | $370.2M | — | ||
| Q2 24 | $575.8M | — | ||
| Q1 24 | $471.4M | — | ||
| Q4 23 | $185.1M | $120.3M |
| Q3 25 | $1.9B | $828.7M | ||
| Q2 25 | $1.2B | $692.9M | ||
| Q1 25 | $1.3B | $704.0M | ||
| Q4 24 | $1.4B | $618.7M | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $830.9M | — | ||
| Q4 23 | $500.8M | $93.5M |
| Q3 25 | $2.1B | $883.1M | ||
| Q2 25 | $1.4B | $606.5M | ||
| Q1 25 | $1.5B | $618.1M | ||
| Q4 24 | $1.6B | $544.7M | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $951.5M | — | ||
| Q4 23 | $628.6M | $224.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-156.2M | $-199.8M |
| Free Cash FlowOCF − Capex | $-156.9M | $-199.9M |
| FCF MarginFCF / Revenue | -1257.6% | -2425.1% |
| Capex IntensityCapex / Revenue | 5.7% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-592.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-156.2M | $-199.8M | ||
| Q2 25 | $-199.7M | $-33.3M | ||
| Q1 25 | $-124.8M | $-22.8M | ||
| Q4 24 | $-99.9M | $-26.4M | ||
| Q3 24 | $-65.6M | — | ||
| Q2 24 | $-65.0M | — | ||
| Q1 24 | $-70.4M | — | ||
| Q4 23 | $16.5M | $-73.2M |
| Q3 25 | $-156.9M | $-199.9M | ||
| Q2 25 | $-203.0M | — | ||
| Q1 25 | $-128.6M | $-22.9M | ||
| Q4 24 | $-103.8M | $-26.5M | ||
| Q3 24 | $-67.3M | — | ||
| Q2 24 | $-65.5M | — | ||
| Q1 24 | $-71.3M | — | ||
| Q4 23 | $15.6M | $-73.3M |
| Q3 25 | -1257.6% | -2425.1% | ||
| Q2 25 | -5277.1% | — | ||
| Q1 25 | -8174.3% | -170.9% | ||
| Q4 24 | -3491.0% | -77.3% | ||
| Q3 24 | -2881.8% | — | ||
| Q2 24 | -3204.6% | — | ||
| Q1 24 | -2012.3% | — | ||
| Q4 23 | 713.1% | -1606.6% |
| Q3 25 | 5.7% | 0.9% | ||
| Q2 25 | 86.9% | — | ||
| Q1 25 | 238.6% | 0.5% | ||
| Q4 24 | 131.7% | 0.1% | ||
| Q3 24 | 72.9% | — | ||
| Q2 24 | 26.0% | — | ||
| Q1 24 | 25.8% | — | ||
| Q4 23 | 39.4% | 1.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RNA
Segment breakdown not available.
SMR
| Power Plant And NPM Engineering Design And Licensing Services And Fees | $8.0M | 97% |
| Other | $208.0K | 3% |
